We are dedicated to transforming cardiovascular muscle diseases.
All of us at Edgewise are committed to developing new medicines for people facing serious cardiovascular diseases with unmet medical needs.
Servier Acquires Our Muscular Dystrophy Program
Following the close of our transaction with Servier, Edgewise’s muscular dystrophy business, including sevasemten, is now part of Servier. Servier’s global capabilities and commitment to neuromuscular diseases position it to advance sevasemten and continue supporting the patient and advocacy communities we have been privileged to serve.
Edgewise is now focused exclusively on advancing high-impact therapies for people living with serious cardiovascular diseases.